132 related articles for article (PubMed ID: 11583007)
1. Susceptibilities of Propionibacterium acnes ophthalmic isolates to moxifloxacin.
Dali P; Giugliano ER; Vellozzi EM; Smith MA
Antimicrob Agents Chemother; 2001 Oct; 45(10):2969-70. PubMed ID: 11583007
[No Abstract] [Full Text] [Related]
2. Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.
Wagner J; Jabbusch M; Eisenblätter M; Hahn H; Wendt C; Ignatius R
Antimicrob Agents Chemother; 2003 Jul; 47(7):2358-61. PubMed ID: 12821499
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.
Hamamoto K; Shimizu T; Fujimoto N; Zhang Y; Arai S
Antimicrob Agents Chemother; 2001 Jun; 45(6):1908-10. PubMed ID: 11353651
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
Hoppe JE; Dalhoff A; Pfründer D
Antimicrob Agents Chemother; 1998 Jul; 42(7):1868. PubMed ID: 9661039
[No Abstract] [Full Text] [Related]
5. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Etest with a conventional agar dilution method in evaluating the in vitro activity of moxifloxacin.
Andrews JM; Wise R
J Antimicrob Chemother; 2000 Feb; 45(2):257-8. PubMed ID: 10660513
[No Abstract] [Full Text] [Related]
7. Susceptibility testing of Propionibacterium acnes comparing agar dilution with E test.
Smith MA; Alperstein P; France K; Vellozzi EM; Isenberg HD
J Clin Microbiol; 1996 Apr; 34(4):1024-6. PubMed ID: 8815076
[TBL] [Abstract][Full Text] [Related]
8. Activity of moxifloxacin against mycobacteria.
Gillespie SH; Billington O
J Antimicrob Chemother; 1999 Sep; 44(3):393-5. PubMed ID: 10511409
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal activity of moxifloxacin against Staphylococcus aureus.
Berrington AW; Perry JD; Gould FK
Clin Microbiol Infect; 2001 Mar; 7(3):161-3. PubMed ID: 11318816
[No Abstract] [Full Text] [Related]
10. In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
J Infect Chemother; 2002 Mar; 8(1):115-7. PubMed ID: 11957133
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 1998 Apr; 42(4):951-2. PubMed ID: 9559818
[TBL] [Abstract][Full Text] [Related]
12. Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
Johnson AP; Warner M; George RC; Livermore DM
J Antimicrob Chemother; 2001 Apr; 47(4):411-5. PubMed ID: 11266412
[TBL] [Abstract][Full Text] [Related]
13. In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus.
Schmitz FJ; Fluit AC; Milatovic D; Verhoef J; Heinz HP; Brisse S
J Antimicrob Chemother; 2000 Jul; 46(1):109-13. PubMed ID: 10882698
[TBL] [Abstract][Full Text] [Related]
14. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.
Giamarellos-Bourboulis EJ; Karnesis L; Galani I; Giamarellou H
Antimicrob Agents Chemother; 2002 Dec; 46(12):3997-9. PubMed ID: 12435710
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae.
Boswell FJ; Andrews JM; Wise R
J Antimicrob Chemother; 2001 Sep; 48(3):446-7. PubMed ID: 11533016
[No Abstract] [Full Text] [Related]
16. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.
Rolain JM; Maurin M; Raoult D
Antimicrob Agents Chemother; 2001 Jan; 45(1):301-2. PubMed ID: 11120982
[TBL] [Abstract][Full Text] [Related]
17. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
Li X; Zhao X; Drlica K
Antimicrob Agents Chemother; 2002 Feb; 46(2):522-4. PubMed ID: 11796368
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
Aktaş Z; Gönüllü N; Salcioğlu M; Bal C; Anğ O
Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; Climent A; Royo G
Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacodynamic profile and clinical efficacy of moxifloxacin ophthalmic solution (Vegamox 0.5% ophthalmic solution].
Watanabe M; Ishizuka K; Ikemoto T
Nihon Yakurigaku Zasshi; 2007 May; 129(5):375-85. PubMed ID: 17507775
[No Abstract] [Full Text] [Related]
[Next] [New Search]
